Gara Jalqabaatti › Myelodysplastic Syndromes › Texas › Houston
Qorannoo klinikaalii Myelodysplastic Syndromes Houston, TX keessatti
Qorannoo 43 Myelodysplastic Syndromes f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1/2
- M D Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Namoota walitti qabaa jiraSadarkaa 1
- M D Anderson Cancer Center, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Namoota walitti qabaa jiraSadarkaa 3
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Md Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- MD Anderson Cancer Center, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1/2
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Namoota walitti qabaa jiraSadarkaa 3
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Namoota walitti qabaa jiraSadarkaa 2
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Namoota walitti qabaa jiraSadarkaa 2/3Hojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Namoota walitti qabaa jiraSadarkaa 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 2
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- MD Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- MDACC, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
Qorannoo Myelodysplastic Syndromes magaalota biroo keessatti
- Baldwin Park, CAQorannoo 26
- New York City, NYQorannoo 21
- Seattle, WAQorannoo 21
- Washington, DCQorannoo 20
- Tampa, FLQorannoo 19
- Boston, MAQorannoo 19
- Miami, FLQorannoo 17
- Durham, NCQorannoo 14
- Columbus, OHQorannoo 14
- St. Louis, MOQorannoo 13
- Atlanta, GAQorannoo 13
- Chicago, ILQorannoo 13
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.